Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE)

University Health Network, Toronto

Status: Enrolling

Conditions: Breast Cancer; Uterine Cancer; Melanoma; Colon Cancer; Cowden Syndrome; Lung Cancer; Cancer; Leukemia; Ovarian Cancer; Mutation; Meningioma; Lynch Syndrome; BRCA2 Mutation; Kidney Cancer; Lymphoma; Myeloma; BRCA1 Mutation; Head and Neck Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03702309

LIBERATE

Details and patient eligibility

About

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.

Enrollment: 2,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
2. Patient must be ≥ 18 years old.
3. All patients must have signed and dated an informed consent form for this LIBERATE study.
4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.

Exclusion criteria

None

Trial design

2,500 participants in 1 patient group

LIBERATE

Description:

Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).